MedSci Healthcare Holdings Limited
HHKEX:24150.85
HKD
-0.03
(-3.41%)
ISIN
KYG5960J1085
CUSIP
G5960J108
Return %
Stock
S&P 500
1Y
-44.81
14.20
3Y
-82.29
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Xinmei Li
- Full Time Employees
- 407
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Building 34 Shanghai SH China 201612
- IPO Date
- Apr 27, 2023
- Website
- medsci.cn
- Similar Companies
- Business
- MedSci Healthcare Holdings Limited operates an online professional physician platform and related health information services in the People’s Republic of China and the United States, delivering precision omni-channel marketing solutions, physician platform services, and real-world research solutions through its MedSci platform. The company focuses on three core businesses: precision omni-channel marketing solutions (precision detailing, medical content creation, online survey services); physician platform solutions (clinical study assistance and academic medical content); and real-world research solutions (design, management and execution of real-world evidence-based research projects). It serves pharmaceutical and medical device companies, physicians, hospitals, and non-profit organizations, with the MedSci platform accessible via website, mobile applications, and social channels such as WeChat mini programs and official accounts. MedSci was founded in 2012 and is headquartered in Shanghai, China, with operations extending into other markets including the United States, and maintains a corporate structure primarily focused on online physician platforms, marketing solutions, and real-world research services across its customer base in the healthcare sector. The company’s product and service offerings are organized around three main offerings: physician platform solutions including clinical study support and medical content; precision marketing solutions including detailing, content creation, and survey services; and real-world research solutions involving study design, data collection, management, and analysis for evidence generation. The business model integrates multi-channel engagement capabilities to support pharmaceutical and device manufacturers in physician outreach, clinical research activities, and real-world data generation, with ongoing strategic initiatives to expand clinical research platforms and data analytics services for hospitals and departments. Recent strategic developments include enhancements to the three-solution synergy, expansion of intelligent-driven clinical research platforms, and the continued scale-up of real-world evidence services to additional hospital networks, reflecting ongoing growth in healthcare data analytics and study execution capabilities. The firm’s geographic footprint encompasses Mainland China and international markets, underscoring its role as a provider of physician platforms, marketing solutions, and real-world research services across multiple regions.